by: Parent Project Muscular Dystrophy
NS Pharma, Inc. announced the launch of NS Support for patients with Duchenne and their healthcare providers. NS Support will provide a resource for patients and doctors to get more information once NS Pharma has an FDA approved therapy. Caregivers and healthcare providers can call to learn more information about NS Support and request notifications about product availability and program enrollment.
We look forward to learning more about NS Support at PPMD’s Virtual Annual Conference later this month.
Read NS Pharma’s Announcement
NS Pharma Announces Launch of Patient Support Hub
PARAMUS, NJ: July 7, 2020 – NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Shigenobu Maekawa), announced today the launch of NS Support for patients with Duchenne muscular dystrophy (DMD) and their healthcare providers.
NS Support can be reached by telephone at 833-677-8778, Monday through Friday from 8 am to 8 pm ET. Caregivers and healthcare providers can call to learn more information about NS Support and request notifications about product availability and program enrollment.
“Based on our conversations with the DMD community, there is a high demand for assistance with navigating the complicated insurance landscape for DMD patients amenable to exon 53 skipping therapy,” said Tsugio Tanaka, President, NS Pharma, Inc. “We want to ensure the smoothest patient experience possible and a rapid journey towards access and treatment. That is why we are launching NS Support now, so we can begin the process of engaging with families who want to learn more about what NS Support can offer.”
